461 related articles for article (PubMed ID: 33057388)
21. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
[TBL] [Abstract][Full Text] [Related]
24. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
[TBL] [Abstract][Full Text] [Related]
25. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
26. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
27. Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension.
Shults NV; Kanovka SS; Ten Eyck JE; Rybka V; Suzuki YJ
J Am Heart Assoc; 2019 Mar; 8(5):e011227. PubMed ID: 30807241
[TBL] [Abstract][Full Text] [Related]
28. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.
Liu A; Schreier D; Tian L; Eickhoff JC; Wang Z; Hacker TA; Chesler NC
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H273-83. PubMed ID: 24906919
[TBL] [Abstract][Full Text] [Related]
29. Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L; Wacker J; Beghetti M; Lador F
Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
[TBL] [Abstract][Full Text] [Related]
30. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
[TBL] [Abstract][Full Text] [Related]
32. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
33. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
Corboz MR; Plaunt AJ; Malinin V; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
Eur J Pharmacol; 2022 Feb; 916():174484. PubMed ID: 34508752
[TBL] [Abstract][Full Text] [Related]
34. Distinct time courses and mechanics of right ventricular hypertrophy and diastolic stiffening in a male rat model of pulmonary arterial hypertension.
Kwan ED; Vélez-Rendón D; Zhang X; Mu H; Patel M; Pursell E; Stowe J; Valdez-Jasso D
Am J Physiol Heart Circ Physiol; 2021 Oct; 321(4):H702-H715. PubMed ID: 34448637
[TBL] [Abstract][Full Text] [Related]
35. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
37. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
[TBL] [Abstract][Full Text] [Related]
38. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Hypertension.
Imano H; Kato R; Nomura A; Tamura M; Yamaguchi Y; Ijiri Y; Wu H; Nakano T; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Asahi M; Hayashi T
Biol Pharm Bull; 2021 May; 44(5):669-677. PubMed ID: 33612567
[TBL] [Abstract][Full Text] [Related]
40. Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
Kato F; Sakao S; Takeuchi T; Suzuki T; Nishimura R; Yasuda T; Tanabe N; Tatsumi K
Am J Physiol Lung Cell Mol Physiol; 2017 Nov; 313(5):L899-L915. PubMed ID: 28798259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
